Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study to Evaluate the Efficacy and Safety of OraVescent Fentanyl Citrate Treatment for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Noncancer-Related Chronic Pain

This study has been completed.
Information provided by:
Teva Pharmaceutical Industries Identifier:
First received: June 21, 2006
Last updated: May 8, 2014
Last verified: May 2014
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: July 2007
  Estimated Primary Completion Date: No date given